Spruce Biosciences (SPRB)

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious neurological disorders with significant unmet medical needs. The company's primary focus is advancing Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), also known as Sanfilippo Syndrome Type B. Spruce develops targeted, first-in-class therapies intended to address rare diseases where treatment options are limited or unavailable. The company is committed to using science-driven approaches to improve outcomes for patients and families affected by severe neurological conditions. Headquartered in South San Francisco, California, Spruce primarily operates within the United States while conducting clinical development activities globally. Its mission is to deliver transformative therapies that meaningfully improve patients' lives.